Acerus Pharmaceuticals

ASP-T

Analysis and Opinions about ASP-T

Signal
Opinion
Expert
HOLD
HOLD
August 25, 2015

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

Show full opinionHide full opinion

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

COMMENT
COMMENT
August 29, 2014

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

Show full opinionHide full opinion

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

DON'T BUY
DON'T BUY
September 6, 2013

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

Show full opinionHide full opinion

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

COMMENT
COMMENT
December 4, 2012

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

Show full opinionHide full opinion

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

HOLD
HOLD
July 30, 2012

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.

Show full opinionHide full opinion

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.

WATCH
WATCH
May 31, 2012
New drug delivery for more testosterone. Got a lot of attention because they are working on the female Viagra. It is a concept stock because they are in trials. If it works out it could be a huge win. But there are no revenue or earnings at this point so there is a lot of ability for downside. A licensing deal would be the catalyst.
Show full opinionHide full opinion
New drug delivery for more testosterone. Got a lot of attention because they are working on the female Viagra. It is a concept stock because they are in trials. If it works out it could be a huge win. But there are no revenue or earnings at this point so there is a lot of ability for downside. A licensing deal would be the catalyst.
Showing 1 to 6 of 6 entries
  • «
  • 1
  • »